TheraRadar
← Back
Data updated: Sep 20, 2026

LINDE GAS EQUIP

Pharma
Pharmaceuticals

LINDE GAS EQUIP is a pharmaceutical company with 2 FDA-approved products.

2022
Since
2
Drugs
-
Trials
6
New Drugs (2yr)
Modality:
2 Small Molecules

LINDE GAS EQUIP's Key Drugs

LINDE GAS EQUIP's core commercial portfolio centers on CARBON DIOXIDE, USP, NITROUS OXIDE, USP — its most strategically important drugs approved in the last 15 years.

CARBON DIOXIDE, USP
Respiratory
Approved 2013
NITROUS OXIDE, USP
Other
Approved 2013

LINDE GAS EQUIP's Recent FDA Approvals

LINDE GAS EQUIP secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

NITROUS OXIDE, USP NDA
2026-08-09
nitrous oxide
CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp

LINDE GAS EQUIP's Therapeutic Areas

Disease areas where LINDE GAS EQUIP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

LINDE GAS EQUIP Pipeline Snapshot

Active clinical trials for LINDE GAS EQUIP across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CARBON DIOXIDE, USP leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling